Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;110(7):1644-1648.
doi: 10.3324/haematol.2024.287062. Epub 2025 Feb 13.

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Cyril Salek  1 , Stepan Hrabovsky  2 , Frantisek Folber  2 , Zdenek Koristek  3 , Jan M Horacek  4 , Eva Fronkova  5 , Leona Rezkova Reznickova  5 , Pavla Pecherkova  6 , Petr Soukup  6 , Barbora Dluhosova  3 , Vaclava Polivkova  6 , Jitka Krizkova  6 , Katerina Machova Polakova  6 , Zuzana Vrzalova  7 , Hana Halamova  7 , Jan Trka  5 , Petr Cetkovsky  8 , Michael Doubek  7
Affiliations

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Cyril Salek et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart illustrating the course of patients through the study. BLINA: blinatumomab; CNS: central nervous system; CR: complete remission; HSCT: hematopoietic stem cell transplantation; IG/TR: immunoglobulin and/or T-cell receptor gene rearrangement; MDS: myelodysplastic neoplasm; MRD: measurable residual disease; N: number; W: week.
See this image and copyright information in PMC

References

    1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. - PMC - PubMed
    1. Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126(23):680.
    1. Gökbuget N, Arnold R, Böhme A, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood. 2007;110(11):12.
    1. Šálek C, Folber F, Froňková E, et al. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol. 2016;96(3):276-284. - PubMed
    1. Šálek C, Hrabovský Š, Folber F, et al. Treatment of adult patients with acute lymphoblastic leukemia in the Czech Republic in the period 2007-2020. Klin Onkol. 2023;36(4):382-395. - PubMed

LinkOut - more resources